Ulcerative Colitis: Mirikizumab with Tirzepatide

We are studying whether combining mirikizumab with tirzepatide helps adults with moderately to severely active ulcerative colitis and obesity achieve better remission and weight loss than mirikizumab alone.

1-2 years 16-20 visits Confirmation phase (III)Partially Remote Standard Medicines Oral InjectionEndocrinologyGastroenterology

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Mirikizumab

Mirikizumab is a lab-made antibody that reduces immune-driven inflammation to treat conditions such as ulcerative colitis and plaque psoriasis.

Tirzepatide

Tirzepatide is a substance that helps lower blood sugar and promote weight loss in people with type 2 diabetes and obesity.

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...

Medical University of Graz

Department of Internal Medicine, Division of Gastroenterology and Hepatology

Graz, Austria

Medizinische Universitaet Innsbruck

Internal Medicine 1

Innsbruck, Austria

Medical University Of Vienna

Department of Internal Medicine III, Division of Gastroenterology and Hepatology

Vienna, Austria

Sponsor: Eli Lilly & Co.

Last updated: Nov 26, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.